Project Grant R15CA297694
Award Date 9/4/25
Completion Date 8/31/26
Dollars Obligated $462K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $194,787 to Northern Michigan University (NMU), Johns Hopkins University (JHU), and the Kennedy Krieger Institute to validate the D2HGLO diagnostic and predictive tool for the quantification of the oncometabolite D-2-hydroxyglutarate (D-2-HG) in glioma. The key products and services to be delivered under this 2-year award (Sep 2025 - Aug 2027) include the...
- This $576,493.00 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to develop sophisticated, self-calibrating near-infrared fluorescent probes that can quantitatively assess microviscosity variations and monitor protein misfolding/aggregation within live cells. The probes are designed to have enhanced water solubility, stability, and cell permeability to maximize biocompatibility and selectivity for detecting viscosity changes and protein...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,820,337.00 to the Regents of the University of Michigan to develop new methods to directly measure metabolic pathway activity in mouse models and patients with glioblastomas (GBMs), which are deadly and incurable brain cancers. The goal is to identify optimal metabolic treatment strategies for GBM patients by evaluating the safety, on-target activity, and potential efficacy of new...
- The University of Michigan received a $136,412 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to conduct research on defining and interrupting metabolic processes that support glioblastoma, an aggressive form of brain cancer. The goal of the 2-year project is to determine how glioblastoma tumors co-opt brain-derived metabolites like glutamine and lactate to fuel tumor growth and therapy resistance. The research will use in vitro models to...
- The University of Michigan was awarded a $2,284,054 Project Grant by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program. The 4-year grant, which began on September 1, 2025, will support research to transform molecular cancer screening through the development of stimulated Raman histology and deep neural networks. The project aims to improve access to molecular cancer testing by creating innovative diagnostic tools and methods...
- This $149,394 Project Grant was awarded on August 1, 2025 by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant supports research led by the University of California, Davis to advance the development of targeted radiopharmaceuticals for cancer diagnosis and therapy. Specifically, the research focuses on designing, synthesizing, and optimizing novel molecular imaging...
- This $683,472 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel targeted therapy for acute myeloid leukemia (AML). The principal investigators at the University of Cincinnati are conducting preclinical research to evaluate a differentiation-inducing agent (HOSU-53) that targets the mitochondrial enzyme DHODH. The goal is to promote AML cell differentiation, activate the immune system, and induce ferroptosis to...
- The U.S. National Cancer Institute (NCI) awarded a $693,781 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), effective April 14, 2025. The grant supports research focused on "Harnessing Mutant IDH1 as a Therapeutic Target in Liver Cancer and Other Solid Malignancies." The key objectives are to understand how IDH1-inhibiting medicines slow cancer growth, why resistance...
- This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
- This $238,722 federal Project Grant awarded on August 18, 2025 by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research supports research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The research aims to define the specific mechanisms that promote mutagenic DNA repair and drive acquired drug resistance in persister cancer cells, focusing on the role of the microhomology-mediated end...